INR Target for Mechanical Heart Valves
For mechanical aortic valves without additional risk factors, target an INR of 2.5 (range 2.0-3.0); for mechanical mitral valves or aortic valves with risk factors, target an INR of 3.0 (range 2.5-3.5). 1
Mechanical Aortic Valve
Standard Risk Patients
- Target INR: 2.5 (range 2.0-3.0) for current-generation bileaflet mechanical aortic valves without additional thromboembolic risk factors 1
- This target provides optimal balance between thromboembolism prevention and bleeding risk
- The 2020 ACC/AHA guidelines clearly demonstrate that moderate-intensity anticoagulation (INR 2.0-3.0) achieves similar thromboembolic protection as higher intensity (INR 3.0-4.5) but with significantly reduced bleeding complications 1
High-Risk Patients
Target INR: 3.0 (range 2.5-3.5) when any of these risk factors are present: 1
- Atrial fibrillation
- Previous thromboembolism
- Hypercoagulable state
- Older-generation prosthesis (e.g., ball-in-cage valve)
- Severe left ventricular dysfunction
Important caveat: Recent evidence challenges the higher INR target for high-risk aortic valve patients. A 2021 study found that standard-intensity anticoagulation (INR 2.5) in patients with additional risk factors was associated with significantly lower rates of bleeding and composite adverse events compared to higher-intensity (INR 3.0), with minimal thromboembolic events in both groups 2. This suggests the guideline recommendation for higher INR may expose patients to unnecessary bleeding risk.
Special Case: On-X Aortic Valve
- After 3 months post-surgery: Target INR 1.5-2.0 plus aspirin 75-100 mg daily may be reasonable in patients without thromboembolic risk factors 1
- However, approach this lower target with caution—case reports document thromboembolic strokes even with INR 2.4 in On-X valves 3
Mechanical Mitral Valve
Target INR: 3.0 (range 2.5-3.5) for all mechanical mitral valves 1
Key Evidence
- Thromboembolism incidence is inherently higher with mitral than aortic mechanical valves
- The GELIA study demonstrated that lower INR ranges (2.0-3.5) were associated with worse survival compared to higher targets (2.5-4.5) in mitral valve patients 1
- The target of 3.0 (range 2.5-3.5) balances efficacy against the practical challenge of maintaining therapeutic range—patients achieve target 74.5% of the time with INR 2.0-3.5 versus only 44.5% with INR 3.0-4.5 1
Critical finding: The 2023 PROACT Mitral trial attempted to validate lower-dose warfarin (INR 2.0-2.5) for On-X mitral valves but failed to achieve noninferiority compared to standard dosing (INR 2.5-3.5) 4. This reinforces that mitral valves require higher anticoagulation intensity regardless of valve type.
Combined Aortic and Mitral Valves
Target INR: 3.0 (range 2.5-3.5) 1
- Treat as mitral valve replacement given the higher thrombogenic risk
Additional Antiplatelet Therapy
- Consider adding aspirin 75-100 mg daily if thromboembolism occurs despite adequate INR 5
- May consider aspirin addition in patients with concomitant atherosclerotic disease, though this increases bleeding risk 5
Common Pitfalls
Failing to reassess INR goals over time: Risk factors change—atrial fibrillation may develop, or patients may reach 3 months post-On-X valve implantation. Periodic review is essential 6
Over-anticoagulating high-risk aortic valve patients: The guideline recommendation for INR 3.0 in high-risk aortic patients may cause more harm than benefit based on recent data 2
Attempting lower INR targets in mitral valves: The PROACT Mitral trial definitively showed this approach is not safe 4
Assuming On-X valves are universally safe at lower INR: Individual patients may require higher targets despite valve type 3